Infect Chemother IC Infection & Chemotherapy 2093-2340 2092-6448 The Korean Society of Infectious Diseases and Korean Society for Chemotherapy 10.3947/ic.2012.44.6.485 Case Report Rifampin-resistant Relapsed Tuberculosis Confirmed by Molecular Technique Moon Song Mi Lee Sang-Oh Choi Sang-Ho Kim Yang Soo Woo Jun Hee Kim Sung-Han Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Correspondence to Sung-Han Kim, M.D. Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, 388-1Pungnap-dong, Songpa-gu, Seoul 138-736, Korea. Tel: +82-2-3010-3305, Fax: +82-2-3010-6970, kimsunghanmd@hotmail.com 12 2012 31 12 2012 44 6 485 490 25 04 2012 24 07 2012 31 07 2012 Copyright © 2012 by The Korean Society of Infectious Diseases and Korean Society for Chemotherapy 2012

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Recurrent tuberculosis can be caused by a relapse of the original infecting strain, a reinfection with a new strain of Mycobacterium tuberculosis or a paradoxical response associated with the anti-tuberculosis treatment. A drug susceptibility test is important when evaluating recurrent tuberculosis but a conventional microbiological test may be unavailable or unsuccessful. Recently, direct molecular testing as a line probe assay (GenoType® MTBDRplus, Hain Lifescience GmbH, Nehren, Germany) has shown promising results for the diagnosis or treatment of drug-resistant tuberculosis. We present two cases of rifampin-resistant, relapsed tuberculosis that were confirmed using a molecular technique.

 Mycobacterium tuberculosis Rifampin Drug resistance Jasmer RM Bozeman L Schwartzman K Cave MD Saukkonen JJ Metchock B Khan A Burman WJ Tuberculosis Trials Consortium Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med 2004 170 1360 1366 A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: results during the 24 months after the end of chemotherapy Am Rev Respir Dis 1982 126 460 462 Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for tuberculosis. Hong Kong Chest Service/British Medical Research Council Am Rev Respir Dis 1987 136 1339 1342 Blumberg HM Burman WJ Chaisson RE Daley CL Etkind SC Friedman LN Fujiwara P Grzemska M Hopewell PC Iseman MD Jasmer RM Koppaka V Menzies RI O'Brien RJ Reves RR Reichman LB Simone PM Starke JR Vernon AA American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis Am J Respir Crit Care Med 2003 167 603 662 Verver S Warren RM Beyers N Richardson M van der Spuy GD Borgdorff MW Enarson DA Behr MA van Helden PD Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis Am J Respir Crit Care Med 2005 171 1430 1435 Palaci M Dietze R Hadad DJ Ribeiro FK Peres RL Vinhas SA Maciel EL do Valle Dettoni V Horter L Boom WH Johnson JL Eisenach KD Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis J Clin Microbiol 2007 45 4064 4066 Chang KC Leung CC Yew WW Ho SC Tam CM A nested case-control study on treatment-related risk factors for early relapse of tuberculosis Am J Respir Crit Care Med 2004 170 1124 1130 Seung KJ Gelmanova IE Peremitin GG Golubchikova VT Pavlova VE Sirotkina OB Yanova GV Strelis AK The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis Clin Infect Dis 2004 39 1321 1328 Espinal MA Kim SJ Suarez PG Kam KM Khomenko AG Migliori GB Baéz J Kochi A Dye C Raviglione MC Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries JAMA 2000 283 2537 2545 Joh JS Lee CH Lee JE Park YK Bai GH Kim EC Han SK Shim YS Yim JJ The interval between initiation of anti-tuberculosis treatment in patients with culture-positive pulmonary tuberculosis and receipt of drug-susceptibility test results J Korean Med Sci 2007 22 26 29 Kim SJ Drug-susceptibility testing in tuberculosis: methods and reliability of results Eur Respir J 2005 25 564 569 Han MD Im JS Yim J Oh DK A Study on the drug susceptibility test of multi-drug resistant tuberculosis patients Korean J Epidemiol 2008 30 301 308 Pai M Kalantri S Dheda K New tools and emerging technologies for the diagnosis of tuberculosis: part II. Active tuberculosis and drug resistance Expert Rev Mol Diagn 2006 6 423 432 Bai GH Park YK Choi YW Bai JI Kim HJ Chang CL Lee JK Kim SJ Trend of anti-tuberculosis drug resistance in Korea, 1994-2004 Int J Tuberc Lung Dis 2007 11 571 576 Yoon NB Lee SW Park SM Jeong IH Park SY Han SY Lee YR Jung JK Kim JM Kim SY Um SJ Lee SK Son C Hong YH Lee KN Roh MS Kim KH The current status of multidrug-resistant tuberculosis in one tertiary hospital in Busan, 2005~2009 Tuberc Respir Dis 2011 71 120 125 Cho OH Park KH Park SY Moon SM Chong YP Kim MN Lee SO Choi SH Woo JH Kim YS Kim SH Drug-resistant extrapulmonary tuberculosis Infect Chemother 2011 43 258 261 Telenti A Imboden P Marchesi F Lowrie D Cole S Colston MJ Matter L Schopfer K Bodmer T Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis Lancet 1993 341 647 650 Musser JM Antimicrobial agent resistance in mycobacteria: molecular genetic insights Clin Microbiol Rev 1995 8 496 514 Wade MM Zhang Y Mechanisms of drug resistance in Mycobacterium tuberculosis Front Biosci 2004 9 975 994 Morgan M Kalantri S Flores L Pai M A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis BMC Infect Dis 2005 5 62 Wilson ML Recent advances in the laboratory detection of Mycobacterium tuberculosis complex and drug resistance Clin Infect Dis 2011 52 1350 1355 Hillemann D Rüsch-Gerdes S Richter E Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens J Clin Microbiol 2009 47 1767 1772 Boehme CC Nabeta P Hillemann D Nicol MP Shenai S Krapp F Allen J Tahirli R Blakemore R Rustomjee R Milovic A Jones M O'Brien SM Persing DH Ruesch-Gerdes S Gotuzzo E Rodrigues C Alland D Perkins MD Rapid molecular detection of tuberculosis and rifampin resistance N Engl J Med 2010 363 1005 1015 Hillemann D Rüsch-Gerdes S Richter E Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens J Clin Microbiol 2007 45 2635 2640 Causse M Ruiz P Gutierrez JB Zerolo J Casal M Evaluation of new GenoType MTBDRplus for detection of resistance in cultures and direct specimens of Mycobacterium tuberculosis Int J Tuberc Lung Dis 2008 12 1456 1460 Huang WL Chen HY Kuo YM Jou R Performance assessment of the GenoType MTBDRplus test and DNA sequencing in detection of multidrug-resistant Mycobacterium tuberculosis J Clin Microbiol 2009 47 2520 2524 Jeong TD An D Sung H Chi HS Kim MN Shim TS Evaluation of the performance of GenoType® MTBDRplus assay for rapid detection of multi-drug resistant Mycobacterium tuberculosis in Sputum Specimens Lab Med Online 2011 1 19 25 Hillemann D Rüsch-Gerdes S Richter E Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens J Clin Microbiol 2007 45 2635 2640

Diagnosis and Treatment of Rifampin-resistant Relapsed Tuberculosis Cases

TB, tuberculosis; AFB, acid-fast bacilli; PCR, polymerase chain reaction; INH, isoniazie; RFP, rifampin, EMB, ethambutol; PZA, pyrazinamide